There was that small Pfizer study in rats that found the treatment group had twice as many early losses as the control group, and there were some fetal malformations. That study was reported to the European Medicines Agency, not published AFAIK, and the EMA did not report any comparison of the rate of fetal malformations in the treatment group to that in the control group.
The EMA report (https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf) said:
>There was an increase (~2x) of pre-implantation loss (9.77%, compared to control 4.09%) although this was within historical control data range (5.1%-11.5%). Among foetuses (from a total of n=21 dams/litters), there was a very low incidence of gastroschisis, mouth/jaw malformations, right sided aortic arch, and cervical vertebrae abnormalities, although these findings were within historical control data. Regarding skeletal findings, the exposed group had comparable to control group levels of presacral vertebral arches supernumerary lumbar ribs, supernumerary lumbar short ribs, caudal vertebrae number < 5). There were no signs of adverse effects on the postnatal pups (terminated at PND21). It is noted that there is currently no available data on the placental transfer of BNT162b2.
They really should have done testing with monkeys, though, because (as you said) their placenta is more similar to humans'.
![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png)
timeasmymeasure
no subject
Date: 2021-11-09 02:22 am (UTC)The EMA report (https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf) said:
>There was an increase (~2x) of pre-implantation loss (9.77%, compared to control 4.09%) although this was within historical control data range (5.1%-11.5%). Among foetuses (from a total of n=21 dams/litters), there was a very low incidence of gastroschisis, mouth/jaw malformations, right sided aortic arch, and cervical vertebrae abnormalities, although these findings were within historical control data. Regarding skeletal findings, the exposed group had comparable to control group levels of presacral vertebral arches supernumerary lumbar ribs, supernumerary lumbar short ribs, caudal vertebrae number < 5). There were no signs of adverse effects on the postnatal pups (terminated at PND21). It is noted that there is currently no available data on the placental transfer of BNT162b2.
They really should have done testing with monkeys, though, because (as you said) their placenta is more similar to humans'.